Literature DB >> 7572822

Primary basaloid squamous cell carcinoma of the trachea.

M G Saltarelli1, M V Fleming, B M Wenig, A A Gal, K A Mansour, W D Travis.   

Abstract

Basaloid squamous cell carcinoma (BSCC) is an unusual but well-established entity, primarily in the upper aerodigestive tract, composed of basaloid cells associated with dysplastic to neoplastic squamous cells, and characterized by an aggressive and rapidly fatal course. To date, BSCC originating in the trachea has not been reported. In this article, the authors describe the clinical, gross, and microscopic pathologic, histochemical, and immunohistochemical features of two cases of BSCC arising in the trachea. Features distinguishing this entity from other, more common tumors of the trachea, including metastases and direct extension from other sites of origin, are also discussed.

Entities:  

Mesh:

Year:  1995        PMID: 7572822     DOI: 10.1093/ajcp/104.5.594

Source DB:  PubMed          Journal:  Am J Clin Pathol        ISSN: 0002-9173            Impact factor:   2.493


  4 in total

Review 1.  Basaloid squamous cell carcinoma of the head and neck: a clinicopathological and follow-up study of 40 cases and review of the literature.

Authors:  Cosme Ereño; Ayman Gaafar; Maddi Garmendia; Carmen Etxezarraga; Francisco J Bilbao; José I López
Journal:  Head Neck Pathol       Date:  2008-03-21

2.  Basaloid squamous carcinoma of esophagus:a clinicopathological, immunohistochemical and electron microscopic study of sixteen cases.

Authors:  Xin-Hua Zhang; Gui-Qin Sun; Xiao-Jun Zhou; Hui-Fang Guo; Tai-He Zhang
Journal:  World J Gastroenterol       Date:  1998-10       Impact factor: 5.742

3.  [Basaloid squamous epithelial carcinoma of the mouth mucosa].

Authors:  K A Grötz; H D Kuffner; M Mitze; T Reichert; W Wagner
Journal:  Mund Kiefer Gesichtschir       Date:  1997-05

4.  Immunoexpression of p53, Ki-67 and E-cadherin in basaloid squamous cell carcinoma of the larynx.

Authors:  María J Rodríguez Tojo; Francisco J García Cano; Juan C Infante Sánchez; E Velázquez Fernández; José M Aguirre Urízar
Journal:  Clin Transl Oncol       Date:  2005-04       Impact factor: 3.405

  4 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.